RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II

Neoplasia

Volumn 9, Issue 12, 2007, Pages 1012-1020

  Maratheftis, Christos I ^a   Giannouli, Stavroula ^a   Spachidou, Maria P ^a   Panayotou, George ^b   Voulgarelis, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

Author keywords

Annexin II; IRF 1; Myelodysplastic syndrome; RNAi; TLR 4

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERFERON REGULATORY FACTOR 1; LIPOCORTIN 2; PROTEIN BAX; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 4;

AMPLICON; APOPTOSIS; ARTICLE; BONE MARROW; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LEUKEMIA CELL; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION;

EID: 37149013022     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07640     Document Type: Article

References (43)

1. Mamane Y, Heylbroeck C, Génin P, Algarté M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R, Hiscott J (1999). Interferon regulatory factors: the next generation. Gene 237 (1), 1-14.
2. Kroger A, Koster M, Schroeder K, Hauser H, and Mueller PP (2002). Activities of IRF-1. J Interferon Cytokine Res 22 (1), 5-14.
3. Fujita T, Kimura Y, Miyamoto M, Barsoumian EL, and Taniguchi T (1989). Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature 337 (6204), 270-272.
4. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T, Taniguchi T (1989). Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58 (4), 729-739.
5. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, Miyata T, Taniguchi T (1988). Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54 (6), 903-913.
6. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H, Taniguchi T (1994). Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 9 (11), 3313-3320.
7. Liebermann DA and Hoffman B (2006). Interferon regulatory factor-1 myelodysplasia and leukemia. Leuk Res 30 (9), 1069-1071.
8. Tanaka N and Taniguchi T (2000). The interferon regulatory factors and oncogenesis. Semin Cancer Biol 10 (2), 73-81.
9. Tzoanopoulos D, Speletas M, Arvanitidis K, Veiopoulou C, Kyriaki S, Thyphronitis G, Sideras P, Kartalis G, Ritis K (2002). Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br J Haematol 119 (1), 46-53.
10. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF, et al. (1993). Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259 (5097), 968-971.
11. Abdollahi A, Lord KA, Hoffman-Liebermann B, and Liebermann DA (1991). Interferon regulatory factor 1 is a myeloid differentiation primary response gene induced by interleukin 6 and leukemia inhibitory factor: role in growth inhibition. Cell Growth Differ 2 (8), 401-407.
12. Rehli M, Poltorak A, Schwarzfischer L, Krause SW, Andreesen R, and Beutler B (2000). PU.1 and interferon consensus sequence-binding protein regulate the myeloid expression of the human Toll-like receptor 4 gene. J Biol Chem 275 (13), 9773-9781.
13. Aderem A and Ulevitch RJ (2000). Toll-like receptors in the induction of the innate immune response. Nature 406 (6797), 782-787.
14. Akira S and Takeda K (2004). Toll-like receptor signalling. Nat Rev Immunol 4 (7), 499-511.
15. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, Chow JC, Strauss JF 3rd (2001). The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 276 (13), 10229-10233.
16. Smiley ST, King JA, and Hancock WW (2001). Fibrinogen stimulates macrophage chemokine secretion through Toll-like receptor 4. J Immunol 167 (5), 2887-2894.
17. Andreakos E, Foxwell B, and Feldmann M (2004). Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 202, 250-265.
18. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997). A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (6640), 394-397.
19. Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA, Hiemstra PS, van't Veer C (2002). In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-gamma and TNF-alpha mediated up-regulation during inflammation. J Immunol 168 (3), 1286-1293.
20. Honda K and Taniguchi T (2006). IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern - recognition receptors. Nat Rev Immunol 6 (9), 644-658.
21. Cioca DP, Aoki Y, and Kiyosawa K (2003). RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines. Cancer Gene Ther 10 (2), 125-133.
22. Donze O and Picard D (2002). RNA interference in mammalian cells using siRNAs synthesized with T7 RNA polymerase. Nucleic Acids Res 30 (10), e46.
23. Maratheftis CI, Bolaraki PE, Giannouli S, Kapsogeorgou EK, Moutsopoulos HM, and Voulgarelis M (2006). Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells. Leuk Res 30 (9), 1177-1186.
24. Maratheftis CI, Andreakos E, Moutsopoulos HM, and Voulgarelis M (2007). Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 13 (4), 1154-1160.
25. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, and Hajjar KA (1999). Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340 (13), 994-1004.
26. Taniguchi T, Lamphier MS, and Tanaka N (1997). IRF-1: the transcription factor linking the interferon response and oncogenesis. Biochim Biophys Acta 1333 (1), M9-M17.
27. Moynagh PN (2005). TLR signalling and activation of IRFs: revisiting old friends fromthe NF-kappaB pathway. Trends Immunol 26 (9), 469-476.
28. Li T, Hu J, and Li L (2004). Characterization of Tollip protein upon lipopolysaccharide challenge. Mol Immunol 41 (1), 85-92.
29. Eklund EA, Jalava A, and Kakar R (1998). PU.1, interferon regulatory factor 1, and interferon consensus sequence - binding protein cooperate to increase gp91(phox) expression. J Biol Chem 273 (22), 13957-13965.
30. Dror N, Alter-Koltunoff M, Azriel A, Amariglio N, Jacob-Hirsch J, Zeligson S, Morgenstern A, Tamura T, Hauser H, Rechavi G, et al. (2007). Identification of IRF-8 and IRF-1 target genes in activated macrophages. Mol Immunol 44 (4), 338-346.
31. Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, and Taniguchi T (1990). Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 63 (2), 303-312.
32. Hajjar KA, Jacovina AT, and Chacko J (1994). An endothelial cell receptor for plasminogen/tissue plasminogen activator: I. Identity with Annexin II. J Biol Chem 269 (33), 21191-21197.
33. 2 expression during cellular differentiation in myeloid cell lines. Biochem Soc Trans 32 (Pt 6), 1122-1123.
34. Daun JM and Fenton MJ (2000). Interleukin-1/Toll receptor family members: receptor structure and signal transduction pathways. J Interferon Cytokine Res 20 (10), 843-855.
35. Aliprantis AO, Yang RB, Weiss DS, Godowski P, and Zychlinsky A (2000). The apoptotic signaling pathway activated by Toll-like receptor-2. Embo J 19 (13), 3325-3336.
36. Fan W, Ha T, Li Y, Ozment-Skelton T, Williams DL, Kelley J, Browder IW, Li C (2005). Overexpression of TLR2 and TLR4 susceptibility to serum deprivation - induced apoptosis in CHO cells. Biochem Biophys Res Commun 337 (3), 840-848.
37. Haase R, Kirschning CJ, Sing A, Schröttner P, Fukase K, Kusumoto S, Wagner H, Heesemann J, Ruckdeschel K (2003). A dominant role of Toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J Immunol 171 (8), 4294-4303.
38. Kawai T, Adachi O, Ogawa T, Takeda K, and Akira S (1999). Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity 11 (1), 115-122.
39. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J, Tschopp J (2000). TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2 (4), 241-243.
40. Haendeler J, Zeiher AM, and Dimmeler S (1996). Vitamin C and E prevent lipopolysaccharide-induced apoptosis in human endothelial cells by modulation of Bcl-2 and Bax. Eur J Pharmacol 317 (2-3), 407-411.
41. Messmer UK, Briner VA, and Pfeilschifter J (1999). Tumor necrosis factor-alpha and lipopolysaccharide induce apoptotic cell death in bovine glomerular endothelial cells. Kidney Int 55 (6), 2322-2337.
42. Kim KY, Shin HK, Choi JM, and Hong KW (2002). Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. J Pharmacol Exp Ther 300 (2), 709-715.
43. Giannouli S, Tzoanopoulos D, Ritis K, Kartalis G, Moutsopoulos HM, and Voulgarelis M (2004). Autoimmune manifestations in human myelodysplasia: a positive correlation with interferon regulatory factor-1 (IRF-1) expression. Ann Rheum Dis 63 (5), 578-582.